Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries. Lead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to provide a brief report on FH status in their countries, including available information, programmes, initiatives, and management. 63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available, data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low rates of FH detection are reported across all regions. National registries and education programmes to improve FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic testing is not widely implemented (frequent cost issues). There are only a few national official government programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are available in ∼2/3 countries. Lipoprotein-apheresis is offered in ∼60% countries, although access is limited. FH is a recognised public health concern. Management varies widely across countries, with overall suboptimal identification and under-treatment. Efforts and initiatives to improve FH knowledge and management are underway, including development of national registries, but support, particularly from health authorities, and better funding are greatly needed.
Introduction: The objective is to study the influence of CYP3A5 (6986A>G), CYP2C9 (430C>T), CYP2C9 (1075A>C), SLCO1B1 (521T>C) and BCRP (ABCG2, 421C>A) gene polymorphisms on the development of simvastatin intolerance in ethnic Uzbek patients with coronary artery disease (CAD). Material and methods: The case group contained 50 patients with clinical simvastatin-induced intolerance symptoms; the control group contained 50 patients without side-effects. Genotyping was performed by means of the PCR-RFLP method. Results: Among 37 patients with simvastatin-induced liver symptoms the *3/*3 genotype of the CYP3A5 gene (p = 0.0001) and variant genotype of the CA BCRP gene were observed more frequently than in the control group (p = 0.0001). However, when the 13 patients who had statin-associated muscle symptoms (SAMS) were compared with the control group (n = 50), it was found that in the case group the 3*/3* genotype of the CYP3A5 gene (OR = 8.6; 95% CI: 2.1–34.1; p = 0.003) and C allele carriers of the gene polymorphism SLCO1B1 (OR = 3.54; 95% CI: 1.35–9.27; χ² = 5.7; p = 0.017) were predominant. Conclusions: The *3/*3 genotype of the CYP3A5 (6986A>G) gene and CA genotype of the BCRP (ABCG2, 421C>A) gene were associated with simvastatin-induced liver symptoms in ethnic Uzbek CAD patients, whereas in patients with simvastatin-associated muscle symptoms (SAMS), the combination of *3/*3 genotype of CYP3A5 (6986A> G) and carriage of the C allele of the SLCO1B1 gene polymorphism was predominant.
28 June 2018 in Archives of Medical Science – Atherosclerotic Diseases
Introduction The aim was to study the pharmacogenetic determinants of switching simvastatin-intolerant ethnic Uzbek patients with coronary artery disease (CAD) to rosuvastatin treatment. Material and methods The study included 50 patients with CAD, who demonstrated statin-induced adverse...
1 January 2021 in Clinical and Experimental Surgery. Petrovsky journal
Aim: Coronary heart disease (CHD) has been the leading cause of death worldwide for several decades. Non-alcoholic fatty liver disease (NAFLD), the most common liver pathology, is considered a risk factor (RF) for the development of CHD and a predictor of an unfavourable prognosis. Our study aimed to compare cardiometabolic parameters in patients with CHD with and without NAFLD. Methods: The study prospectively included 85 patients with CHD, 61 with NAFLD (group I) and 24 without NAFLD (group II). In both groups, a comparative analysis of RF, anthropometric parameters, lipidogram, glycemic profile, brachiocephalic arteries (BCA) ultrasound (USD), and heart structural and geometric parameters according to echocardiography (EchoCG) and coronary calcium (CC) parameters was performed. Results: Patients with CHD and NAFLD had statistically significantly higher levels of total cholesterol, very low-density lipoproteins, triglycerides, insulin, heart structural parameters, and CC. Conclusions: Thus, the relationship between NAFLD and CHD is two-way, and liver diseases can exacerbate the course of cardiovascular diseases (CVD).